Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05960370
Other study ID # Compaction Study
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 15, 2022
Est. completion date October 15, 2024

Study information

Verified date July 2023
Source Instituto Bernabeu
Contact Esperanza E de la Torre Pérez, Gynecologist
Phone +34625072082
Email espe_delatorre@hotmail.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Multicenter prospective observational cohort study, comparing ongoing pregnancy rates in natural cycles for euploid embryo transfer in patients who present endometrial compaction at the time of the transfer versus those who have a stable or greater endometrial thickness with respect to the estrogenic phase.


Description:

Multicenter prospective observational cohort study. Based on our sample size calculation, the study group will consist of 206 women (exposed or "compaction" group: 103 women with a decrease of ≥ 5% in endometrial thickness between the estrogenic phase and the day of embryo transfer; non-exposed "non-compaction" group: 103 women with similar or greater endometrial thickness between these time points). The main objective of this study is to compare the ongoing pregnancy rates in natural cycles for euploid embryo transfer in patients who present endometrial compaction at the time of transfer versus those who with a stable or greater endometrial thickness with respect to the estrogenic phase. The estimated duration of the study is 24-30 months. Inclusion criteria are: 18 to 50 years of age, with primary or secondary infertility, subjected to endometrial preparation in a modified natural cycle for transfer of a genetically euploid blastocyst, from their own oocyte or oocyte donation, with a normal uterine cavity. Exclusion criteria are: uterine or endometrial disease (e.g., multiple myomatosis, severe adenomyosis, Asherman syndrome, refractory endometrium), conditions that prevent correct ultrasound assessment (tilted uterus), or a history of recurrent implantation failure or repeated miscarriages.


Recruitment information / eligibility

Status Recruiting
Enrollment 206
Est. completion date October 15, 2024
Est. primary completion date June 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Aged 18 to 50 years - Primary or secondary infertility - Normal uterine cavity - Endometrial preparation in a modified natural cycle for single embryo transfer - Embryo in blastocyst state from own oocyte or oocyte donation cycles, who had normal results on preimplantation genetic testing for aneuploidy (PGT-A) via trophectoderm biopsy. Exclusion Criteria: - Uterine or endometrial disease (multiple myomatosis [>3 fibroids of > 3 cm], adenomyosis, Asherman syndrome) - Difficulties in correctly measuring endometrial thickness due to a retroverted or tilted uterus - History of recurrent implantation failure (3 or more transferred blastocysts of good quality, from their own oocyte [<35 years] or oocyte donation); recurrent early Pregnancy Loss (the loss of two or more pregnancies before 10 weeks of gestational age. - Suboptimal endometrial response (endometrium < 6 mm on the day of ovulation triggering).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Observational non intervention study
An additional control scan will be performed vaginally the day of the embryo transfer. Rest of follow up and treatment will be executed as usually.

Locations

Country Name City State
Spain Instituto Bernabeu Madrid

Sponsors (2)

Lead Sponsor Collaborator
Instituto Bernabeu Universidad Miguel Hernandez de Elche

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ongoing pregnancy rate Presence of an intrauterine pregnancy with positive embryo heartbeat as seen by sonography at 8-10 weeks gestational age. 8-10 weeks gestational age.
Secondary Biochemical pregnancy loss Spontaneous pregnancy demise based on decreasing serum b-hCG levels, without an ultrasound evaluation. 9-10 days after the embryo transfer.
Secondary Clinical pregnancy A pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy. 5-6 weeks gestational age.
Secondary Ectopic pregnancy ultrasonic or surgical visualization of a pregnancy outside of the endometrial cavity. 5-8 weeks gestational age.
Secondary Early pregnancy loss spontaneous pregnancy demise before 10 weeks of gestational age (before 8th developmental week). 5-10 weeks gestational age.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03504345 - Progesterone Supplementation in Frozen Embryo Transfer Cycles N/A
Not yet recruiting NCT04240860 - Autologous Intrauterine Platelet-Rich Plasma Instillation And Endometrial Scratching for Thinned Endometrium Phase 2
Recruiting NCT06322498 - Inflammation Markers in Fluid Aspirate From a Scarred Uterine vs. a Normal Uterine Cavity N/A
Completed NCT03374163 - Effect Of Intravenous IntralipidTherapyon Pregnancy Outcome in Women With History of Recurrent Implantation Failure Undergoing Intracytoplasmic Sperm Injection-Embryo Transfer Cycle: A Randomized Controlled Trial Phase 2